<p>Moderna Inc said on Thursday it was developing a single-dose vaccine that combines a booster dose against Covid-19 and a booster against flu.</p>.<p>"Our number one priority as a company right now is to bring to market a Pan-respiratory annual booster vaccine, which we plan to always customize and upgrade," Chief Executive Officer Stéphane Bancel said during Moderna's R&D day.</p>.<p>The company provided updates on its ongoing mid-stage trial testing its authorized Covid-19 vaccine in children aged 6 months to less than 12 years.</p>.<p>Moderna's vaccine, which received its emergency authorization for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.</p>.<p>As part of the pediatric trial, the company said it will test 50 micrograms of its vaccine in a study group of 4,000 children between 6 years and less than 12 years.</p>.<p>Moderna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years age groups, were still underway.</p>.<p>Rival vaccine from Pfizer Inc and German partner BioNTech was authorized for ages 12 to 15 years earlier this year.</p>.<p>Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and Covid-19 vaccine.</p>
<p>Moderna Inc said on Thursday it was developing a single-dose vaccine that combines a booster dose against Covid-19 and a booster against flu.</p>.<p>"Our number one priority as a company right now is to bring to market a Pan-respiratory annual booster vaccine, which we plan to always customize and upgrade," Chief Executive Officer Stéphane Bancel said during Moderna's R&D day.</p>.<p>The company provided updates on its ongoing mid-stage trial testing its authorized Covid-19 vaccine in children aged 6 months to less than 12 years.</p>.<p>Moderna's vaccine, which received its emergency authorization for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.</p>.<p>As part of the pediatric trial, the company said it will test 50 micrograms of its vaccine in a study group of 4,000 children between 6 years and less than 12 years.</p>.<p>Moderna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years age groups, were still underway.</p>.<p>Rival vaccine from Pfizer Inc and German partner BioNTech was authorized for ages 12 to 15 years earlier this year.</p>.<p>Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and Covid-19 vaccine.</p>